Fundraising Fox

Samarth Kulkarni

Chief Executive Officer and Chairman of the Board at CRISPR

United States

Find your path to Samarth

1,294 people in our graph share verified history with Samarth — schools, employers, funds. One of them is your warm intro.

Laura BuhlerunlockedSamarth: together at McKinsey & Company (2009–2012)
×9Samarth: together at McKinsey & Company
×2Samarth: together at University of Washington

About

Samarth Kulkarni has served as Chief Executive Officer of CRISPR Therapeutics since 2017, having joined the company in 2015 as Chief Business Officer and subsequently serving as President and Chief Business Officer. Before CRISPR Therapeutics, he was a Partner at McKinsey & Company, where he co-led the biotech practice within the firm's Pharmaceutical and Medical Products practice. He holds a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B.Tech. from the Indian Institute of Technology, and currently serves on the boards of Centessa Pharmaceuticals, Black Diamond Therapeutics, and Repare Therapeutics.

Chief Executive Officer and Chairman of the Board at CRISPR

Intro paths

→

In turn, Samarth can intro founders to CRISPR's investors below.

CRISPR's investors · 4

AbingworthLondon · $15M – $30M checksAvoro Capital AdvisorsNew YorkNew Enterprise Associates (NEA)Menlo Park · $200K – $40M checksVersant VenturesSan Francisco · $250K – $5M checks

Co-founders at CRISPR

EC
Emmanuelle CharpentierCo-founder

Experience

  1. CRISPR TherapeuticsChief Executive Officercurrent2017 — presentGreater Boston Area
  2. CRISPR TherapeuticsPresident2017Greater Boston Area
  3. CRISPR TherapeuticsChief Business Officer2015 — 2017Cambridge, Massachussetts
  4. Centessa PharmaceuticalsBoard Membercurrent2021 — present
  5. Black Diamond TherapeuticsBoard Membercurrent2019 — present
  6. Repare TherapeuticsBoard Membercurrent2019 — present
  7. McKinsey & CompanyPrincipal (Partner)2013 — 2015San Francisco Bay Area
  8. McKinsey & CompanyAssociate Principal2006 — 2013
  9. University of WashingtonResearch Scientist2000 — 2006

Skills & more

Biotechnology50Medical Devices31Nanotechnology19R&D10Personalized medicineHardware Diagnostics7Personalized Medicine8Commercialization9Pharmaceutical Industry28Lifesciences15Biomedical Engineering1Clinical Development3
+10 moreTechnology TransferBiochemistryStrategyCompetitive AnalysisCorporate DevelopmentCross-functional Team LeadershipVenture CapitalStart-upsMarket EntryProduct Management

From Samarth's professional profile.

Frequently asked questions

Who is Samarth Kulkarni?
Samarth Kulkarni has served as Chief Executive Officer of CRISPR Therapeutics since 2017, having joined the company in 2015 as Chief Business Officer and subsequently serving as President and Chief Business Officer. Before CRISPR Therapeutics, he was a Partner at McKinsey & Company, where he co-led the biotech practice within the firm's Pharmaceutical and Medical Products practice. He holds a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B.Tech. from the Indian Institute of Technology, and currently serves on the boards of Centessa Pharmaceuticals, Black Diamond Therapeutics, and Repare Therapeutics.
Where does Samarth Kulkarni work?
Samarth Kulkarni is Chief Executive Officer and Chairman of the Board at CRISPR.
Where did Samarth Kulkarni go to school?
Samarth Kulkarni studied at Indian Institute of Technology, Kharagpur (B.Tech, Biotechnology & Biochemical Engg); University of Washington (Doctor of Philosophy - PhD, Bioengineering and Nanotechnology).

Same school

Also attended Indian Institute of Technology, Kharagpur243

SomnathTechnology Partner and Chief Data Scientist at Clear VenturesMoiz SaifeePartner, Analytics at Correlation VenturesVasu MurthyCPO Fellow at Mighty CapitalNesara S RInvestment Analyst at A91 PartnersFiona FernandezInvestor at SynconaBiplab AdhyaManaging Partner at Wipro Ventures

+ 237 more

Also attended University of Washington608

Andrew ChenGeneral Partner at Andreessen HorowitzArvind JainFounder & CEO of GleanJane MooneyCo-founder & VP, Strategy and Finance at Collaborative RoboticsVictoria TreygerGeneral Partner at Felicis VenturesAndrewAdvisor at Clear VenturesJoe HorsmanInvestor at Madrona Venture Group

+ 602 more

Shared employers

Also worked at CRISPR Therapeutics16

Briggs MorrisonEntrepreneur Partner at MPM BioImpactJerel DavisManaging Director at Versant VenturesJohn LeonardExecutives in Residence at GENERAL INCEPTIONKurt von EmsterManaging Partner at AbingworthMaria FardisVenture Partner at Frazier Life SciencesTony HoInvestor at Pivotal Life Sciences

+ 10 more

Also worked at Centessa Pharmaceuticals3

Aaron KantoffManaging Partner at Scion Life SciencesDr Arjun GoyalInvestment committee member at Tin Alley VenturesJohn CrowleyExecutive Officer at Merus

Also worked at Black Diamond Therapeutics5

Alex MaywegManaging Director at Versant VenturesRachel HumphreyFounding Chief Executive Officer at NormunityDavid M EpsteinExecutive Officer, Director at Aset TherapeuticsElizabeth L. MontgomeryChief People Officer at ConvergentrxAnna KohlmannExecutive Officer at Launchpad Therapeutics, Inc.

Also worked at Repare Therapeutics1

Jerel DavisManaging Director at Versant Ventures